To establish a rationale and platform for targeting ROR1 with mAb-based therapies in B-ALL, the current study employed flow cytometry, Western blotting, immunohistochemistry (IHC), and confocal immunofluorescence microscopy. This evidence concerns the gene ROR1 and acute lymphoblastic leukemia.